{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T04:52:34Z","timestamp":1792644754459,"version":"4.5.0"},"reference-count":60,"publisher":"Oxford University Press (OUP)","issue":"8","license":[{"start":{"date-parts":[[2019,1,29]],"date-time":"2019-01-29T00:00:00Z","timestamp":1548720000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Immunoglobulin A nephropathy (IgAN) was defined as a mesangiopathic disease, since the primary site of deposition of IgA immune material is the mesangium, and proliferation of mesangial cells and matrix excess deposition are the first histopathologic lesions. However, the relentless silent progression of IgAN is mostly due to the development of persistent proteinuria, and recent studies indicate that a major role is played by previous damage of function and anatomy of podocytes. In IgAN, the podocytopathic changes are the consequence of initial alterations in the mesangial area with accumulation of IgA containing immune material. Podocytes are therefore affected by interactions of messages originally driven from the mesangium. After continuous insult, podocytes detach from the glomerular basement membrane. This podocytopathy favours not only the development of glomerular focal and segmental sclerosis, but also the progressive renal function loss. It is still debated whether these lesions can be prevented or cured by corticosteroid\/immunosuppressive treatment. We aimed to review recent data on the mechanisms implicated in the podocytopathy present in IgAN, showing new molecular risk factors for progression of this disease. Moreover, these observations may indicate that the target for new drugs is not only focused on decreasing the activity of mesangial cells and inflammatory reactions in IgAN, but also on improving podocyte function and survival.<\/jats:p>","DOI":"10.1093\/ndt\/gfy413","type":"journal-article","created":{"date-parts":[[2018,12,21]],"date-time":"2018-12-21T15:57:02Z","timestamp":1545407822000},"page":"1280-1285","source":"Crossref","is-referenced-by-count":60,"title":["Podocytopathy in the mesangial proliferative immunoglobulin A nephropathy: new insights into the mechanisms of damage and progression"],"prefix":"10.1093","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6921-4811","authenticated-orcid":false,"given":"Hern\u00e1n","family":"Trimarchi","sequence":"first","affiliation":[{"name":"Nephrology Service, Hospital Brit\u00e1nico de Buenos Aires, Buenos Aires, Argentina"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosanna","family":"Coppo","sequence":"additional","affiliation":[{"name":"Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2019,1,29]]},"reference":[{"key":"2019080503545395000_gfy413-B1","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nrneph.2014.92","article-title":"Pathology of IgA nephropathy","volume":"10","author":"Roberts","year":"2014","journal-title":"Nat Rev Nephrol"},{"key":"2019080503545395000_gfy413-B2","first-page":"139","article-title":"KDIGO Clinical Practice Guideline for Glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B3","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B4","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford Classification for IgA Nephropathy 2016. An update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B5","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.kint.2016.09.029","article-title":"Evidence from the Oxford Classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy","volume":"91","author":"Bellur","year":"2017","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B7","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1016\/j.ekir.2018.03.013","article-title":"Immunosuppressive treatment in children with IgA nephropathy and the clinical value of podocytopathic features","volume":"3","author":"Cambier","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2019080503545395000_gfy413-B8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1152\/physrev.00020.2002","article-title":"Cell biology of the glomerular podocyte","volume":"83","author":"Pavenstadt","year":"2003","journal-title":"Physiol Rev"},{"key":"2019080503545395000_gfy413-B9","doi-asserted-by":"crossref","first-page":"2502","DOI":"10.1046\/j.1523-1755.2000.00434.x","article-title":"Effect of plasma fractions from patients with focal and segmental glomerulosclerosis on rat proteinuria","volume":"58","author":"Le Berre","year":"2000","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B10","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1016\/j.kint.2016.01.012","article-title":"Podocyte injury and its consequences","volume":"89","author":"Nagata","year":"2016","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B11","doi-asserted-by":"crossref","first-page":"F333","DOI":"10.1152\/ajprenal.00478.2012","article-title":"The podocyte\u2019s response to stress: the enigma of foot process effacement","volume":"304","author":"Kriz","year":"2013","journal-title":"Am J Physiol Renal Physiol"},{"key":"2019080503545395000_gfy413-B12","first-page":"103","article-title":"Primary focal and segmental glomerulosclerosis and suPAR: Where do we stand and where are we heading to?","volume":"2","author":"Trimarchi","year":"2013","journal-title":"World J Nephrol"},{"key":"2019080503545395000_gfy413-B13","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1681\/ASN.2018020200","article-title":"Maintenance and breakdown of glomerular tuft architecture","volume":"29","author":"Kriz","year":"2018","journal-title":"J Am Soc Nephrol"},{"key":"2019080503545395000_gfy413-B14","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1007\/s40620-016-0271-z","article-title":"Podocyturia in Fabry adult untreated and treated patients. A controlled study","volume":"29","author":"Trimarchi","year":"2016","journal-title":"J Nephrol"},{"key":"2019080503545395000_gfy413-B15","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1159\/000481633","article-title":"A review of podocyte biology","volume":"47 (Suppl 1)","author":"Garg","year":"2018","journal-title":"Am J Nephrol"},{"key":"2019080503545395000_gfy413-B16","doi-asserted-by":"crossref","first-page":"2975","DOI":"10.1091\/mbc.12.10.2975","article-title":"Urokinase receptors promote beta1 integrin function through interactions with integrin alpha3 beta1","volume":"12","author":"Wei","year":"2001","journal-title":"Mol Biol Cell"},{"key":"2019080503545395000_gfy413-B17","doi-asserted-by":"crossref","first-page":"982","DOI":"10.15252\/embr.201541681","article-title":"Urokinase links plasminogen activation and cell adhesion by cleavage of the RGD motif in vitronectin","volume":"17","author":"De Lorenzi","year":"2016","journal-title":"EMBO Rep"},{"key":"2019080503545395000_gfy413-B18","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1038\/nm1696","article-title":"Modification of kidney barrier function by the urokinase receptor","volume":"14","author":"Wei","year":"2008","journal-title":"Nat Med"},{"key":"2019080503545395000_gfy413-B19","doi-asserted-by":"crossref","first-page":"1390","DOI":"10.1172\/JCI20402","article-title":"Induction of B7-1 in podocytes is associated with nephrotic syndrome","volume":"113","author":"Reiser","year":"2004","journal-title":"J Clin Invest"},{"key":"2019080503545395000_gfy413-B20","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1007\/s10157-017-1489-3","article-title":"Interaction of CD80 with Neph1: a potential mechanism of podocyte injury","volume":"22","author":"Khullar","year":"2018","journal-title":"Clin Exp Nephrol"},{"key":"2019080503545395000_gfy413-B21","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1007\/s00467-013-2679-1","article-title":"CD80 and suPAR in patients with minimal change disease and focal segmental glomerulosclerosis: diagnostic and pathogenic significance","volume":"29","author":"Cara-Fuentes","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"2019080503545395000_gfy413-B22","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1186\/s12967-016-1049-8","article-title":"Increased urinary CD-80 excretion and podocyturia in Fabry disease","volume":"14","author":"Trimarchi","year":"2016","journal-title":"J Transl Med"},{"key":"2019080503545395000_gfy413-B23","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1159\/000473888","article-title":"In IgA nephropathy, glomerulosclerosis is associated with increased urinary CD80 excretion and uPAR-positive podocyturia","volume":"7","author":"Trimarchi","year":"2017","journal-title":"Nephron Extra"},{"key":"2019080503545395000_gfy413-B24","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/ki.2010.460","article-title":"Focal segmental glomerulosclerosis plays a major role in the progression of IgA nephropathy. II. Light microscopic and clinical studies","volume":"79","author":"El Karoui","year":"2011","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B25","doi-asserted-by":"crossref","first-page":"195","DOI":"10.3109\/01913121003648402","article-title":"Morphometric analysis of podocyte foot process effacement in IgA nephropathy and its association with proteinuria","volume":"34","author":"Choi","year":"2010","journal-title":"Ultrastruct Pathol"},{"key":"2019080503545395000_gfy413-B26","doi-asserted-by":"crossref","first-page":"1475","DOI":"10.1046\/j.1523-1755.2002.00269.x","article-title":"Podocytopenia and disease severity in IgA nephropathy","volume":"61","author":"Lemley","year":"2002","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B27","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.2215\/CJN.08110811","article-title":"Relationships between levels of urinary podocalyxin, number of urinary podocytes, and histologic injury in adult patients with IgA nephropathy","volume":"7","author":"Asao","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019080503545395000_gfy413-B28","doi-asserted-by":"crossref","first-page":"1140","DOI":"10.1093\/ndt\/gfv104","article-title":"Urine podocyte mRNAs mark disease activity in IgA nephropathy","volume":"30","author":"Fukuda","year":"2015","journal-title":"Nephrol Dial Transplant"},{"key":"2019080503545395000_gfy413-B29","doi-asserted-by":"crossref","first-page":"1733","DOI":"10.1681\/ASN.2005020159","article-title":"Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria","volume":"16","author":"Yu","year":"2005","journal-title":"J Am Soc Nephrol"},{"key":"2019080503545395000_gfy413-B30","doi-asserted-by":"crossref","first-page":"221","DOI":"10.5527\/wjn.v6.i5.221","article-title":"Podocyturia. Potential applications and current limitations","volume":"6","author":"Trimarchi","year":"2017","journal-title":"World J Nephrol"},{"key":"2019080503545395000_gfy413-B31","first-page":"85","article-title":"La identificaci\u00f3n de podocitos urinarios. la utilidad potencial de un biomarcador novedoso de da\u00f1o gomerular en las glomerulopat\u00edas primarias y secundarias","volume":"13","author":"Trimarchi","year":"2015","journal-title":"Un Estudio Piloto Nefrolog\u00eda Argentina"},{"key":"2019080503545395000_gfy413-B32","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1016\/j.semnephrol.2018.05.018","article-title":"Role of mesangial-podocytes-tubular cross-talk in IgA nephropathy","volume":"38","author":"Leung","year":"2018","journal-title":"Semin Nephrol"},{"key":"2019080503545395000_gfy413-B33","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/ki.2009.473","article-title":"Aberrantly glycosylated IgA1 induces mesangial cells to produce platelet-activating factor that mediates nephrin loss in cultured podocytes","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B34","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2019080503545395000_gfy413-B35","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.nephro.2018.02.004","article-title":"Recent advances in the pathophysiology of IgA nephropathy","volume":"14 (Suppl 1)","author":"Monteiro","year":"2018","journal-title":"Nephrol Ther"},{"key":"2019080503545395000_gfy413-B36","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1093\/ndt\/gfn441","article-title":"Podocyte injury induced by mesangial-derived cytokines in IgA nephropathy","volume":"24","author":"Lai","year":"2008","journal-title":"Nephrol Dial Transplant"},{"key":"2019080503545395000_gfy413-B37","doi-asserted-by":"crossref","first-page":"e73425","DOI":"10.1371\/journal.pone.0073425","article-title":"Synergistic effect of mesangial cell-induced CXCL1 and TGF-\u03b21 in promoting podocyte loss in IgA nephropathy","volume":"8","author":"Zhu","year":"2013","journal-title":"PLoS One"},{"key":"2019080503545395000_gfy413-B38","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1016\/j.clim.2009.04.004","article-title":"Crosstalk between peroxisome proliferator-activated receptor-gamma and angiotensin II in renal tubular epithelial cells in IgA nephropathy","volume":"132","author":"Xiao","year":"2009","journal-title":"Clin Immunol"},{"key":"2019080503545395000_gfy413-B39","doi-asserted-by":"crossref","first-page":"E20","DOI":"10.25011\/cim.v32i1.5083","article-title":"Serum IgA1 from patients with IgA nephropathy up-regulates integrin-linked kinase synthesis and inhibits adhesive capacity in podocytes through indirect pathways","volume":"1","author":"Ye","year":"2009","journal-title":"Clin Invest Med"},{"key":"2019080503545395000_gfy413-B40","doi-asserted-by":"crossref","first-page":"93","DOI":"10.33549\/physiolres.933670","article-title":"Molecular profiling in IgA nephropathy and focal and segmental glomerulosclerosis","volume":"67","author":"Ticova","year":"2018","journal-title":"Physiol Res"},{"key":"2019080503545395000_gfy413-B41","doi-asserted-by":"crossref","first-page":"e0132869","DOI":"10.1371\/journal.pone.0132869","article-title":"Plasma soluble urokinase receptor level is correlated with podocytes damage in patients with IgA nephropathy","volume":"13","author":"Zhao","year":"2015","journal-title":"PLoS One"},{"key":"2019080503545395000_gfy413-B42","doi-asserted-by":"crossref","first-page":"888","DOI":"10.1111\/j.1523-1755.2004.00477.x","article-title":"Clinical significance of costimulatory molecules CD80\/CD86 expression in IgA nephropathy","volume":"65","author":"Wu","year":"2004","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B43","first-page":"626","article-title":"Innate immunity and IgA nephropathy","volume":"23","author":"Coppo","year":"2010","journal-title":"J Nephrol"},{"key":"2019080503545395000_gfy413-B44","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1007\/s11255-017-1760-2","article-title":"Crosstalk between TLR4 and Notch1 signaling in the IgA nephropathy during inflammatory response","volume":"50","author":"Sheng","year":"2018","journal-title":"Int Urol Nephrol"},{"key":"2019080503545395000_gfy413-B45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1365-2249.2009.04045.x","article-title":"Toll-like receptor 4 expression is increased in circulating mononuclear cells of patients with immunoglobulin A nephropathy","volume":"159","author":"Coppo","year":"2010","journal-title":"Clin Exp Immunol"},{"key":"2019080503545395000_gfy413-B46","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1007\/s00467-014-2807-6","article-title":"Toll-like receptors, immunoproteasome and regulatory T cells in children with Henoch-Sch\u00f6nlein purpura and primary IgA nephropathy","volume":"29","author":"Donadio","year":"2014","journal-title":"Pediatr Nephrol"},{"key":"2019080503545395000_gfy413-B47","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/S0272-6386(03)00411-6","article-title":"Detection of nuclear factor-kappaB in IgA nephropathy using Southwestern histochemistry","volume":"42","author":"Ashizawa","year":"2003","journal-title":"Am J Kidney Dis"},{"key":"2019080503545395000_gfy413-B48","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1038\/ki.2008.579","article-title":"Upregulation of the immunoproteasome in peripheral blood mononuclear cells of patients with IgA nephropathy","volume":"75","author":"Coppo","year":"2009","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B49","doi-asserted-by":"crossref","first-page":"9833","DOI":"10.1038\/s41598-017-10490-z","article-title":"Loss of the podocyte glucocorticoid receptor exacerbates proteinuria after injury","volume":"7","author":"Zhou","year":"2017","journal-title":"Sci Rep"},{"key":"2019080503545395000_gfy413-B50","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1046\/j.1523-1755.2000.00417.x","article-title":"Integrin expression and IgA nephropathy: in vitro modulation by IgA with altered glycosylation and macromolecular IgA","volume":"58","author":"Peruzzi","year":"2000","journal-title":"Kidney Int"},{"key":"2019080503545395000_gfy413-B51","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1016\/j.ekir.2017.02.019","article-title":"Efficacy and safety of sparsentan compared with irbesartan in patients with primary focal segmental glomerulosclerosis: randomized, controlled trial design (DUET)","volume":"2","author":"Komers","year":"2017","journal-title":"Kidney Int Rep"},{"key":"2019080503545395000_gfy413-B52","doi-asserted-by":"crossref","first-page":"2063","DOI":"10.1194\/jlr.M085704","article-title":"Modulation of inflammatory platelet-activating factor (PAF) receptor by the acyl analogue of PAF","volume":"59","author":"Chaithra","year":"2018","journal-title":"J Lipid Res"},{"key":"2019080503545395000_gfy413-B53","doi-asserted-by":"crossref","first-page":"i25","DOI":"10.1093\/ndt\/gft271","article-title":"Proteasome inhibitors in progressive renal diseases","volume":"29 (Suppl 1)","author":"Coppo","year":"2014","journal-title":"Nephrol Dial Transplant"},{"key":"2019080503545395000_gfy413-B54","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.ekir.2018.03.001","article-title":"Bortezomib for reduction of proteinuria in IgA nephropathy","volume":"3","author":"Hartono","year":"2018","journal-title":"Kidney Int Rep"},{"key":"2019080503545395000_gfy413-B55","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1159\/000487330","article-title":"Effects of hydroxychloroquine on proteinuria in immunoglobulin A nephropathy","volume":"47","author":"Yang","year":"2018","journal-title":"Am J Nephrol"},{"key":"2019080503545395000_gfy413-B56","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1093\/ndt\/gfr612","article-title":"Amiloride off-target effect inhibits podocyte urokinase receptor expression and reduces proteinuria","volume":"27","author":"Zhang","year":"2012","journal-title":"Nephrol Dial Transplant"},{"key":"2019080503545395000_gfy413-B57","first-page":"1492743","article-title":"Podocyturia. A clue for the rational use of amiloride in Alport renal disease","volume":"2016","author":"Trimarchi","year":"2016","journal-title":"Case Rep Nephrol"},{"key":"2019080503545395000_gfy413-B58","first-page":"1","article-title":"Amiloride as an alternate adjuvant antiproteinuric agent in Fabry disease. The potential roles of plasmin and uPAR","author":"Trimarchi","year":"2014","journal-title":"Case Rep Nephrol"},{"key":"2019080503545395000_gfy413-B59","first-page":"129531","article-title":"In acute IgA nephropathy, proteinuria and creatinine are in the spot, but podocyturia operates in silence. Any place for amiloride?","volume":"2017","author":"Trimarchi","year":"2017","journal-title":"Case Rep Nephrol"},{"key":"2019080503545395000_gfy413-B60","doi-asserted-by":"crossref","first-page":"2","DOI":"10.2174\/1872214809666150302104542","article-title":"Abatacept in glomerular diseases. The open road for the second signal as a new target is settled down","volume":"9","author":"Trimarchi","year":"2015","journal-title":"Recent Pat Endocr Metab Immune Drug Discov"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/8\/1280\/29096769\/gfy413.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,8,5]],"date-time":"2019-08-05T03:55:53Z","timestamp":1564977353000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/8\/1280\/5303938"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1,29]]},"references-count":60,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2019,1,29]]},"published-print":{"date-parts":[[2019,8,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy413","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,8]]},"published":{"date-parts":[[2019,1,29]]}}}